查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1461374

全球肌红蛋白市场：现况分析与预测（2023-2030）

Myoglobin Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 134 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于诊断测试的增加，全球肌红蛋白市场规模预计将稳定成长在 4.32% 左右。 例如，2023年6月，Shineco, Inc.的控股子公司Changzhou Biowin Pharmaceutical Co., Ltd.获得国家药品监督管理局江苏局批准开展三种主要心臟标誌物和一种心臟标誌物的联合检测。心臟5 分钟测试已获得行销和分销批准，该测试只需一次测试即可检测心肌肌钙蛋白I、肌红蛋白和心臟脂肪酸结合蛋白，用于急性心肌梗塞的临床诊断。 在预测期内，有几个因素正在推动市场成长，例如心血管疾病和肌炎的增加，以及医疗保健领域投资的增加。 除此之外，肌红蛋白诊断效率的提升带来了有效的治疗程序，这也稳定地推动了肌红蛋白市场的发展。

依产品类型，市场分为人类肌红蛋白、动物肌红蛋白等。 由于包括心肌梗塞在内的心血管疾病病例不断增加，兽用肌红蛋白细分市场将在 2022 年占据市场主导地位。 兽医肌红蛋白在科学研究中得到了广泛的研究，特别是在生物化学、食品科学和营养学等领域。 研究人员正在研究肌红蛋白的各个方面，包括其结构、功能和特性，以便更好地瞭解其在人体中的作用。 因此，在产品类型中，动物肌红蛋白细分市场在 2022 年占据了重要的市场占有率。

根据应用，市场分为诊断和治疗。 由于临床试验数量不断增加，预计治疗领域在预测期内将以高复合年增长率成长。 例如，2023 年 4 月，CytoSorbents, Inc. 评估了使用 CytoSorb 作为需要肾臟替代治疗的横纹肌溶解症患者标准护理的辅助手段进行体外治疗肌红蛋白的可行性。 製药公司和学术机构正在投资研发，以开发针对淋巴球性视网膜病变的新型治疗策略。 治疗领域的成长是由技术创新、盛行率不断提高、医疗保健服务的改善以及对早期介入和联合治疗方法的日益重视所推动的。 因此，从应用来看，治疗领域预计在预测期内将表现出更高的复合年增长率。

根据最终用户，市场分为医院、诊所和其他。 由于全球因心血管疾病住院的人数不断增加，医院细分市场占据了市场主导地位。 这是因为医院中配备了大多数诊断设备，因此医院的诊断测试正在增加。 除此之外，医院数量的增加也推动了该领域的成长。 例如，根据美国医院协会的数据，截至 2022 年 10 月，美国约有 6,093 家医院，其中包括由非营利组织以及州和地方政府营运的社区医院。 因此，2022年医院在肌红蛋白市场中占有很大占有率。

为了更瞭解肌红蛋白的市场介绍，将市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）、亚太地区（中国、日本、印度、亚太地区其他地区）和世界其他地区。 预计在预测期内，亚太地区全球肌红蛋白市场将以高复合年增长率成长。 预测期内临床试验数量的快速增加、可近性的提高以及医疗保健成本的多样化等因素正在推动市场成长。 此外，心血管疾病的增加也对市场成长产生正面影响。 例如，过去几十年来，印度冠心病的盛行率在农村地区为1.6%至7.4%，在城市地区为1%至13.2%。 该地区是主要心血管疾病宣传项目和产品发布的地点。 因此，预计亚太地区在预测期内将呈现更高的复合年增长率。

市场的主要营运公司包括 Merck KGaA、Abbott、F. Hoffmann-La Roche Ltd、Siemens Healthcare Private Limited、Thermo Fisher Scientific Inc.、OriGene Technologies, Inc.、Innovative Research、Worthington Biochemical Corporation 和 Hyasen Biotechnology公司。

目录

第一章市场介绍

  • 市场定义
  • 主要目标
  • 利害关係人
  • 限制

第二章研究方法/先决条件

  • 调查过程
  • 调查方法
  • 受访者简介

第三章市场总结

第 4 章执行摘要

第 5 章 COVID-19 对肌红蛋白市场的影响

第 6 章肌红蛋白市场收入，2020-2030

第 7 章市场分析：依产品类型

  • 人类肌红蛋白
  • 动物用肌红蛋白
  • 其他

第 8 章市场分析：依应用

  • 诊断
  • 处理中

第 9 章市场分析：依最终使用者划分

  • 医院
  • 诊断实验室
  • 其他

第 10 章市场分析：依地区

  • 北美
    • 美国
    • 加拿大
    • 北美其他地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太地区其他地区
  • 其他领域

第 11 章肌红蛋白市场动态

  • 市场驱动因素
  • 市场问题
  • 影响分析

第 12 章肌红蛋白市场机会

第十三章肌红蛋白市场趋势

第 14 章需求/供给分析

  • 需求方分析
  • 供给面分析

第 15 章价值链分析

第16章比赛场景

  • 竞争状况
    • 波特五力分析

第十七章公司简介

  • Merck KGaA
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthcare Private Limited
  • Thermo Fisher Scientific Inc.
  • OriGene Technologies, Inc.
  • Innovative Research
  • Worthington Biochemical Corporation
  • Hyasen Biotechnology Co., Ltd.
  • RayBiotech, Inc.

第十八章免责声明

简介目录
Product Code: UMHE212679

Myoglobin is a protein found in muscle tissues that binds oxygen, storing it for use during muscle activity. It gives meat its red color and plays a crucial role in oxygen transport and storage within muscle cells. Myoglobin levels in the blood serve as a biomarker for certain medical conditions, particularly those affecting muscle tissue. Elevated levels of myoglobin indicate muscle damage or disease, such as rhabdomyolysis, myocardial infarction, or muscular dystrophy. Innovations in assay development and a rising number of clinical trials are leading to the growth of the market. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are driving the myoglobin market globally.

The Myoglobin Market is expected to grow at a steady rate of around 4.32% owing to the rising number of diagnostic test launches in the market. For instance, in June 2023, Changzhou Biowin Pharmaceutical Co., Ltd., a majority-owned subsidiary of Shineco, Inc. received marketing and distribution approval for its Cardiac 5-Minute Test from the Jiangsu Bureau of the National Medical Products Administration, which is a combination test of three major cardiac markers and can detect cardiac troponin I, myoglobin, and heart fatty acid binding protein for the clinical diagnosis of acute myocardial infarction in one test. Several factors, including rising cardiovascular disorders and myositis, and rising investments in healthcare departments are driving the market's growth during the forecast period. Apart from this, accelerated diagnosis efficiency using myoglobin has resulted in effective treatment procedures which are also driving this market of myoglobin at a steady rate.

Based on the product type, the market is segmented into human myoglobin, animal myoglobin, and others. The animal myoglobin segment dominated the market in the year 2022 owing to the rising cases of cardiovascular diseases including myocardial infarction. Animal myoglobin is extensively studied in scientific research, particularly in fields such as biochemistry, food science, and nutrition. Researchers investigate various aspects of myoglobin, including its structure, function, and properties, to better understand its role in the human body. Thus, among the product types, the animal myoglobin segment held a significant market share in 2022.

Based on the application, the market is bifurcated into diagnosis and treatment. The treatment segment is expected to grow with a high CAGR during the forecast period because of the rising number of clinical trials. For instance, In April 2023, CytoSorbents, Inc. initiated a clinical trial to assess the feasibility of the extracorporeal therapy for the removal of myoglobin using the CytoSorb as an adjunct to the standard of care in patients with rhabdomyolysis requiring renal replacement therapy. Pharmaceutical companies and academic institutions are investing in research and development to develop novel treatment strategies for lymphatic retinopathy. The growth of the treatment segment is driven by technological innovation, increasing disease prevalence, improved access to healthcare services, and a growing emphasis on early intervention and combination therapy approaches. Thus, the treatment segment among applications is expected to witness a higher CAGR during the forecast period.

Based on end user, the market is categorized into hospitals, clinics, and others. The hospital segment is dominating the market owing to the rising hospital admissions for cardiovascular diseases globally. This is due to higher diagnostic tests in hospitals as most diagnostic equipment is available in hospital settings. Apart from this, the growing number of hospitals is also propelling segmental growth. For instance, according to the American Hospital Association, there were about 6,093 hospitals in the U.S. in October 2022, which comprises community hospitals run by non-profit organizations as well as by state and local governments. Thus, hospitals held a significant share of the myoglobin market in 2022.

For a better understanding of the market adoption of myoglobin, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with a high CAGR in the global myoglobin market in the forecast period. Several factors such as a surge in the number of clinical trials being performed, enhanced accessibility, and diversified healthcare costs are driving the market's growth during the forecast period. Further, the increase in incidences of cardiovascular disorders is also having a positive impact on the market's growth. For instance, coronary heart disease prevalence rates in India have ranged from 1.6% to 7.4% in rural populations and from 1% to 13.2% in urban populations in the past several decades. There have been major awareness programs regarding cardiovascular diseases and product launches in the region. Thus, APAC is expected to witness a higher CAGR during the forecast period.

Some of the major players operating in the market include Merck KGaA; Abbott; F. Hoffmann-La Roche Ltd; Siemens Healthcare Private Limited; Thermo Fisher Scientific Inc.; OriGene Technologies, Inc.; Innovative Research; Worthington Biochemical Corporation; Hyasen Biotechnology Co., Ltd.; RayBiotech, Inc.

TABLE OF CONTENTS

1MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Myoglobin Market
  • 2.2.Research Methodology of the Myoglobin Market
  • 2.3.Respondent Profile

3MARKET SYNOPSIS

4EXECUTIVE SUMMARY

5IMPACT OF COVID-19 ON THE MYOGLOBIN MARKET

6MYOGLOBIN MARKET REVENUE (USD BN), 2020-2030F

7MARKET INSIGHTS BY PRODUCT TYPE

  • 7.1.Human Myoglobin
  • 7.2.Animal Myoglobin
  • 7.3.Others

8MARKET INSIGHTS BY APPLICATION

  • 8.1.Diagnosis
  • 8.2.Treatment

9MARKET INSIGHTS BY END USER

  • 9.1.Hospitals
  • 9.2.Diagnostic Laboratories
  • 9.3.Others

10MARKET INSIGHTS BY REGION

  • 10.1.North America
    • 10.1.1.U.S.
    • 10.1.2.Canada
    • 10.1.3.Rest of North America
  • 10.2.Europe
    • 10.2.1.Germany
    • 10.2.2.U.K.
    • 10.2.3.France
    • 10.2.4.Italy
    • 10.2.5.Spain
    • 10.2.6.Rest of Europe
  • 10.3.Asia-Pacific
    • 10.3.1.China
    • 10.3.2.Japan
    • 10.3.3.India
    • 10.3.4.Rest of Asia-Pacific
  • 10.4.Rest of World

11MYOGLOBIN MARKET DYNAMICS

  • 11.1.Market Drivers
  • 11.2.Market Challenges
  • 11.3.Impact Analysis

12MYOGLOBIN MARKET OPPORTUNITIES

13MYOGLOBIN MARKET TRENDS

14DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1.Demand Side Analysis
  • 14.2.Supply Side Analysis

15VALUE CHAIN ANALYSIS

16COMPETITIVE SCENARIO

  • 16.1.Competitive Landscape
    • 16.1.1.Porters Fiver Forces Analysis

17COMPANY PROFILED

  • 17.1.Merck KGaA
  • 17.2.Abbott
  • 17.3.F. Hoffmann-La Roche Ltd
  • 17.4.Siemens Healthcare Private Limited
  • 17.5.Thermo Fisher Scientific Inc.
  • 17.6.OriGene Technologies, Inc.
  • 17.7.Innovative Research
  • 17.8.Worthington Biochemical Corporation
  • 17.9.Hyasen Biotechnology Co., Ltd.
  • 17.10.RayBiotech, Inc.

18DISCLAIMER